KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Operating Expenses (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Operating Expenses data on record, last reported at $2.0 billion in Q4 2025.

  • For Q4 2025, Operating Expenses rose 5.2% year-over-year to $2.0 billion; the TTM value through Dec 2025 reached $7.8 billion, down 30.44%, while the annual FY2025 figure was $7.8 billion, 30.44% down from the prior year.
  • Operating Expenses reached $2.0 billion in Q4 2025 per VRTX's latest filing, up from $1.9 billion in the prior quarter.
  • Across five years, Operating Expenses topped out at $6.2 billion in Q2 2024 and bottomed at $836.5 million in Q1 2021.
  • Average Operating Expenses over 5 years is $1.7 billion, with a median of $1.5 billion recorded in 2023.
  • Peak YoY movement for Operating Expenses: soared 319.98% in 2024, then crashed 70.56% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $1.2 billion in 2021, then grew by 6.22% to $1.3 billion in 2022, then rose by 20.49% to $1.5 billion in 2023, then increased by 23.33% to $1.9 billion in 2024, then grew by 5.2% to $2.0 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $2.0 billion in Q4 2025, $1.9 billion in Q3 2025, and $1.8 billion in Q2 2025.